CXCL8 and rheumatoid arthritis: As previously reported, a single-dose infusion of IRL201805 in RA patents led to the significant inhibition of inflammatory biomarkers C-reactive protein (CRP), IL-8 and vascular endothelial growth factor (VEGF) specifically in IRL201805Res patients when compared to the placebo (Pbo) group.